Sailu Sarvagalla

Sailu Sarvagalla

Auto-generated profile, based on publicly available information

Sailu Sarvagalla

Division of Biology, Indian Institute of Science Education and Research (IISER)-Tirupati, Tirupati, AP, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Autophagy
Verified
Journal Article
Open access
TLTzu-Yu Lin
Tzu-Yu Lin
HCHsiu-Han Chan
Hsiu-Han Chan
SCShang-Hung Chen
Shang-Hung Chen
SSSailu Sarvagalla
Sailu Sarvagalla
PCPai-Sheng Chen
Pai-Sheng Chen
Chun Hei Antonio CheungChun Hei Antonio Cheung
Chun Hei Antonio Cheung
BIRC5/Survivin is known as a dual cellular functions protein that directly regulates both apoptosis and mitosis in embryonic cells during embryogenesis and in cancer cells during tumorigenesis and ...

10 July 2015 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
SSSailu Sarvagalla
Sailu Sarvagalla
MCMohane Coumar
Mohane Coumar
Aurora kinase A, B and C, are key regulators of mitosis and are over expressed in many of the human cancers, making them an ideal drug target for cancer chemotherapy. Currently, over a dozen of Aurora kinase inhibitors are in various phases of clinical development. The majority of the inhibitors (VX-680/MK-0457, PHA-739358, CYC116, SNS-314, AMG 900, AT-9283, SCH- 1473759, ABT-348, PF-03814735, R-763/AS-703569, KW-2449 and TAK-901) are pan-selective (isoform non-selective) and few are Aurora A (MLN8054, MLN8237, VX-689/MK5108 and ENMD 2076) and Aurora B (AZD1152 and GSK1070916) sub-type selective. Despite the intensive research efforts in the past decade, no Aurora kinase inhibitor has reached the market. Recent evidence suggests that the sub-type selective Aurora kinase A inhibitor could possess advantages over pan-selective Aurora inhibitors, by avoiding Aurora B mediated neutropenia. However, sub-type selective Aurora kinase A inhibitor design is very challenging due to the similarity in the active site among the isoforms. Structural biology and computational aspects pertaining to the design of Aurora kinase inhibitors were analyzed and found that a possible means to develop sub-type selective inhibitor is by targeting Aurora A specific residues (Leu215, Thr217 and Arg220) or Aurora B specific residues (Arg159, Glu161 and Lys164), near the solvent exposed region of the protein. Particularly, a useful strategy for the design of sub-type selective Aurora A inhibitor could be by targeting Thr217 residue as in the case of MLN8054. Further preclinical and clinical studies with the sub-type selective Aurora inhibitors could help bring them to the market for the treatment of cancer.

1 April 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
ASAshutosh Singh
Ashutosh Singh
PKPrateek Kumar
Prateek Kumar
SSSailu Sarvagalla
Sailu Sarvagalla
TBTaniya Bharadwaj
Taniya Bharadwaj
NNNamyashree Nayak
Namyashree Nayak
NGNeha Garg
Neha Garg
Protein–protein interactions drive various biological processes in healthy as well as disease states. The transcription factor c-Myc plays a crucial role in maintaining cellular homeostasis, and its deregulated expression is linked to various human cancers; therefore, it can be considered a viable target for cancer therapeutics. However, the structural heterogeneity of c-Myc due to its disordered nature poses a major challenge to drug discovery. In the present study, we used an in silico alanine scanning mutagenesis approach to identify “hot spot” residues within the c-Myc/Myc-associated factor X interface, which is highly disordered and has not yet been systematically analyzed for potential small molecule binding sites. We then used the information gained from this analysis to screen potential inhibitors using a conformation ensemble approach. The fluorescence-based biophysical experiments showed that the identified hit molecules displayed noncovalent interactions with these hot spot residues, and further cell-based experiments showed substantial in vitro potency against diverse c-Myc-expressing cancer/stem cells by deregulating c-Myc activity. These biophysical and computational studies demonstrated stable binding of the hit compounds with the disordered c-Myc protein. Collectively, our data indicated effective drug targeting of the disordered c-Myc protein via the determination of hot spot residues in the c-Myc/Myc-associated factor X heterodimer.

1 August 2019 in Protein Expression and Purification
Verified
Journal Article
Closed access
STShing-Ling Tsai
Shing-Ling Tsai
YCYung-Chieh Chang
Yung-Chieh Chang
SSSailu Sarvagalla
Sailu Sarvagalla
SWShuying Wang
Shuying Wang
MCMohane Coumar
Mohane Coumar
Chun Hei Antonio CheungChun Hei Antonio Cheung
Chun Hei Antonio Cheung